26 February 2008 in Nephrology Dialysis Transplantation
Catheter-related bacteraemia (CRB) is a major cause of morbidity and mortality in haemodialysis patients. Interdialytic locking of catheters with antimicrobial agents has recently been investigated for the prevention of CRB. We performed a meta-analysis of randomized controlled trials (RCT) to determine the efficacy of antimicrobial lock solutions (ALS) in the prevention of CRB in haemodialysis patients. We collected from Medline, Web of Science, the Cochrane Library and major nephrology journals, all relevant references (January 1990-March 2007). We selected RCT comparing an ALS to a standard heparin lock in CRB prevention. We extracted data concerning study quality, patient characteristics and CRB incidence. The relative risk (RR) of CRB was calculated as Ln (CRB incidence control/CRB incidence experimental) using both a fixed- and a random-effects model. Eight studies were included, involving 829 patients, 882 catheters and 90 191 catheter-days. The use of an ALS significantly decreased the risk of CRB (RR 0.32; 95% CI 0.10-0.42). Borderline heterogeneity was observed in the fixed-effects model (Q = 14.42; P = 0.071). Despite the under-representation of small negative studies, the high number of additional trials necessary to reverse the final effect strengthens the confidence in the overall results. Subgroup analyses stratified by the presence of diabetes, duration of follow-up, biochemical markers, proportion of tunnelled cuffed catheters, intranasal mupirocin use and citrate use in the ALS did not show significant differences, except a higher efficacy of gentamicin-containing lock solutions (P = 0.003). The use of ALS reduces by about a factor 3 the risk of CRB in haemodialysis patients. The achieved absolute incidence is similar to the best-published figures (presumably related to stricter hygienic measures). The limited follow-up of the studies does not exclude the onset of adverse events or bacterial resistance with longer use of ALS.
1 March 2011 in American Journal of Kidney Diseases
31 January 2009 in Nephrology Dialysis Transplantation
Background. The K/DOQI guidelines recommend the use of albumin-corrected calcium (Ca), phosphate, parathyroid hormone (PTH) and calcium-phosphate product as therapeutic targets. The two most common assays for measuring albumin yield discordant results in uraemic patients, the Bromcresol purple (BCP) method providing lower albumin values than the Bromcresol green one (BCG). The aim of this study was to assess the impact of the assay on corrected Ca and, thus, on reaching recommended K/DOQI targets for corrected Ca and CaxP product. Methods. We measured plasma albumin (both by BCG and BCP), total Ca and phosphate in all our chronic hemodialysis (HD) patients. Total Ca was corrected (“adjusted”) for albumin level by a formula proposed by the K/DOQI. Results. 89 patients were included, aged 71.2 ± 11.5 years, on chronic hemodialysis for 29 (1-362) months. Albumin level was 3.78 ± 0.24 g/dL by BCG and 3.12 ± 0.27 by BCP ( p < 0.0001). Based on BCG albumin levels there were 12 cases of “hypocalcaemia” (10 mg/dL) and 74 cases with “normal” Ca. The corresponding albumin levels were 3.9 ± 0.2; 3.1 ± 0.6 and 3.8 ± 0.2 g/dL, respectively. According to BCP albumin levels, only one patient was labelled as hypocalcaemia , 21 as hypercalcaemia et 67 as “normal” adjusted Ca (albumin 3.1; 3 ± 0.3 and 3.2 ± 0.3 g/dL, respectively). Depending on the use of BCG or BCP, a discrepancy was thus observed in 29 cases (32.6%): 18 cases were classified as hypercalcaemia when albumin was measured by BCP but were considered normal using BCG, whereas 11 cases classified as hypocalcaemia with BCG had normal adjusted Ca with BCP. Concerning CaxP product, 7 discrepancies were detected. Discussion and conclusion. The choice of either BCG or BCP has a major impact on albumin-adjusted Ca and thus on reaching K/DOQI targets for Ca and CaxP product. Clinicians should take this fact into account for the interpretation of laboratory values and the prescription of drugs related to mineral metabolism and dialysate calcium concentration. The type of assay used for the measurement of albumin should also be recorded and its impact taken into account (or corrected) in multicentric studies and registries.
19 April 2010 in Nephrology Dialysis Transplantation
In the July 2009 issue of the journal Clinical Infectious Diseases, the Infectious Diseases Society of America (IDSA) published an update of their ‘Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection’ [1]. The largest part of the IDSA text relates to non-dialysis catheters, and it is not always clear to what extent these general recommendations can be extrapolated to the haemodialysis condition. A specific but only brief section (∼2 pages) of the IDSA guidelines is devoted to haemodialysis catheters.
26 April 2010 in Clinical Kidney Journal
In the July 2009 issue of the journal Clinical InfectiousDiseases, the Infectious Diseases Society of America (IDSA) published an update of their ‘Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection’ [1]. The largest part of the IDSA text relates to non-dialysis catheters, and it is not always clear how far these general recommendations can be extrapolated to the haemodialysis condition. A specific section of the IDSA guidelines is, however, devoted to haemodialysis catheters.
7 July 2010 in Nephrology Dialysis Transplantation
KDOQI guidelines recommend preparation for renal replacement therapy (RRT) once stage 4 chronic kidney disease (CKD) is reached. Recent studies conducted in the general population and in patients referred to nephrologists have shown that CKD patients, especially the elderly, are much more likely to die than to reach RRT. We investigated whether futile preparation for RRT was performed in CKD patients referred to our nephrology department. We included all patients (n = 386) with stage 4 CKD and without prior RRT, seen at our outpatient clinic between 1 November 2004 and 30 April 2007. Demographics, clinical and laboratory data at inclusion were collected. Follow-up continued until 1 November 2007 or later (last appointment or study outcome). The primary outcome was death without requiring RRT, and secondary outcomes were RRT, going through our pre-dialysis education programme (PDEP) and undergoing the creation of an arterio-venous fistula (AVF). Factors predicting these outcomes were analysed. During complete follow-up (average 23.4 months), 47 patients (12.1%) died without requiring RRT and 59 patients (15.3%) started RRT. The rate of death without requiring RRT in the overall cohort increased from 50 years onwards and exceeded that of RRT in incident patients aged ≥ 80 years. A structured PDEP was offered to 66.1% of patients starting RRT vs 14.9% of patients dying without requiring RRT and 13.9% of patients surviving without requiring RRT (P < 0.001). In addition, 53.3% of patients starting haemodialysis had a prior AVF creation vs 6.4% of patients dying without requiring RRT and 5.7% of patients surviving without requiring RRT (P < 0.001). The risk of death exceeds that of RRT in stage 4 CKD incident patients aged ≥ 80 years referred to our clinic. Futile preparation for RRT was relatively uncommon (14.9%). We were able to largely avoid futility at the expense of incomplete exposure of patients who eventually started RRT, to the structured PDEP, and of a relatively low (53%) level of AVF created prior to start of HD. Whether and how these figures can be improved will require further investigation.